BioInvent discovers and develops monoclonal antibody drugs for cancer immunotherapy, with a clinical-stage pipeline aimed at improving how the immune system attacks tumours. Its proprietary F.I.R.S.T platform screens for novel antibody candidates against hard-to-treat cancers. The company partners with larger pharma groups while advancing its own immuno-oncology programmes.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 21.4 | — | -116.9 | — |
| Q1 2025 | 22.1 | — | -116.6 | — |
| Q2 2025 | 198.1 | — | 38.8 | — |
| Q4 2025 | 3 | -85.9% | -125.8 | — |
| Q1 2026 | 13.4 | -39.1% | -119.2 | — |
All markets — KeepWinning global stock screener
Other companies on Stockholm: Inission AB (publ) (INISS B), Flerie AB (publ) (FLERIE), BICO Group AB (publ) (BICO), Midsona AB (publ) (MSON B), Byggmästare Anders J Ahlström Holding AB (publ) (AJA B), Cheffelo AB (publ) (CHEF)